The Oxford AHSN has helped NHS partners across the region secure funding totalling more than £300,000 to develop services in line with national priorities.
The funds will speed up the integration of proven clinical innovations into everyday practice, bringing tangible patient benefits. They include:
- redeveloping asthma pathways, with a particular focus on treatments for severe asthma, working with Oxford University Hospitals and the Buckinghamshire, Oxfordshire and Berkshire West Integrated Care System
- delivering FeNO* testing to aid asthma diagnosis by installing monitors in four primary care network areas (Banbury, Berinsfield, Bracknell and Oxford)
- transforming the lipid management pathway to reduce cholesterol, working with the new Bedfordshire, Luton and Milton Keynes Clinical Commissioning Group
They were among 51 projects nationwide supported through the £2.8m Pathway Transformation Fund.
The Oxford AHSN is the national lead for Asthma Biologics which can transform the lives of people affected by severe asthma by reducing asthma attacks, asthma-related hospital admissions and the long-term side effects of other treatments such as oral steroids. Our Clinical Innovation Adoption and Strategic & Industry Partnerships teams are working closely with neighbouring Wessex AHSN on asthma pathways and diagnosis.
Read more about the Asthma Biologics workstream and other innovations we’re helping to get into everyday clinical practice.
- In further successful joint funding bids, the Oxford AHSN’s Strategic and Industry Partnerships team and partners secured more than £5m through the first two rounds of the NHS Artificial Intelligence in Health and Care Award.
* FeNO = fractional exhaled nitric oxide (FeNO)